IP Library › Granted Patent US 12,351,880
Granted Patent B2
US 12,351,880 · App. 19/029,541 · Granted Jul 8, 2025

Methods of detecting and enriching circulating tumor DNA

Inventors: Jared Robert Maguire (San Francisco, CA); Clement S. Chu (San Francisco, CA); Imran Saeedul Haque (San Francisco, CA); Eric Andrew Evans (San Bruno, CA); Noah Welker (Half Moon Bay, CA)
Assignee: Myriad Women's Health, Inc.
C12Q1/6886C12Q1/6818C12Q1/6874G01N35/0099C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,880
App. No.
19/029,541
Granted
Jul 8, 2025
Kind
B2
Abstract

The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.

Claims (56)

1. A method of detecting circulating tumor DNA (ctDNA) in a sample, comprising:

sequencing DNA from a tumor sample obtained from a subject with a history of cancer and sequencing DNA from a non-tumor sample from the subject, thereby obtaining sequence reads from the tumor sample and sequence reads from the non-tumor sample;

obtaining a fluid sample from the subject;

enriching, from a cell free DNA (cfDNA) sample from the subject, a DNA fraction of fragments comprising one or more of a set of tumor-specific somatic mutations that are specific to the subject, wherein the set of tumor-specific somatic mutations are present in the sequence reads from the tumor sample but not present in the sequence reads from the non-tumor sample;

sequencing the DNA fraction, thereby obtaining a plurality of sequence reads; and

detecting in the plurality of sequence reads the presence of a sequence read comprising any one of the set of tumor-specific somatic mutations, wherein the presence of a sequence read comprising any one of the set of tumor-specific somatic mutations indicates the presence of ctDNA in the fluid sample.

2. The method of claim 1 , wherein the set of tumor-specific somatic mutations comprises at least 10 different tumor-specific somatic mutations.

3. The method of claim 1 , wherein sequencing DNA from the tumor sample and sequencing DNA from the non-tumor sample comprises whole genome sequencing or whole exome sequencing.

4. The method of claim 1 , wherein the cfDNA sample is extracted from a fluid sample from the subject.

5. The method of claim 4 , wherein the fluid sample is a whole blood sample, a plasma sample, or a serum sample.

6. The method of claim 1 , wherein enriching the DNA fraction comprises hybrid capture-based enrichment, PCR-target enrichment, or on-sequencer enrichment.

7. The method of claim 1 , the cfDNA sample is obtained one or more times during a cancer treatment, following completion of a cancer treatment, while the subject is in remission, or coinciding with or prior to surgery.

8. A method of enriching a sample comprising circulating tumor DNA (ctDNA), comprising:

extracting cell-free DNA (cfDNA) from a fluid sample obtained from a subject with a history of cancer;

enriching, from the extracted cfDNA, fragments comprising one or more of a set of tumor-specific somatic mutations via

(i) hybrid capture-based enrichment,

(ii) PCR-target enrichment, or

(iii) on-sequencer enrichment,

thereby obtaining a DNA fraction comprising ctDNA;

wherein the set of tumor-specific somatic mutations is specific to the subject based on a comparison of sequence reads from sequencing DNA from a tumor sample from the subject and sequence reads from sequencing DNA from a non-tumor sample from the subject.

9. The method of claim 8 , wherein the set of tumor-specific somatic mutations comprises at least 10 different tumor-specific somatic mutations.

10. The method of claim 8 , wherein sequencing DNA from the tumor sample and sequencing DNA from the non-tumor sample comprises whole genome sequencing or whole exome sequencing.

11. The method of claim 8 , wherein the fluid sample is a whole blood sample, a plasma sample, or a serum sample.

12. The method of claim 8 , wherein enriching comprises hybrid capture-based enrichment.

13. The method of claim 8 , wherein enriching comprises PCR-target enrichment.

14. The method of claim 8 , the fluid sample is obtained one or more times during a cancer treatment, following completion of a cancer treatment, while the subject is in remission, or coinciding with or prior to surgery.

15. The method of claim 8 , further comprising sequencing the DNA fraction, thereby obtaining a plurality of sequence reads; and

detecting in the plurality of sequence reads the presence of a sequence read comprising any one of the set of tumor-specific somatic mutations, wherein the presence of a sequence read comprising any one of the set of tumor-specific somatic mutations indicates the presence of ctDNA in the fluid sample.

16. A method of detecting circulating tumor DNA (ctDNA) in a sample, comprising:

sequencing DNA from a tumor sample obtained from a subject with a history of cancer and sequencing DNA from a non-tumor sample from the subject, thereby obtaining sequence reads from the tumor sample and sequence reads from the non-tumor sample;

determining a set of tumor-specific somatic mutations based on the sequence reads from the tumor sample and the sequence reads from the non-tumor sample, and selecting a subset of tumor-specific somatic mutations that are specific to the subject;

enriching, from a cell free DNA (cfDNA) sample from the subject, a DNA fraction of fragments comprising one or more of the subset of tumor-specific somatic mutations;

sequencing the DNA fraction, thereby obtaining a plurality of sequence reads; and

detecting in the plurality of sequence reads the presence of a sequence read comprising any one of the subset of tumor-specific somatic mutations, wherein the presence of a sequence read comprising any one of the subset of tumor-specific somatic mutations indicates the presence of ctDNA in the fluid sample.

17. The method of claim 16 , wherein the subset of tumor-specific somatic mutations comprises at least 10 different tumor-specific somatic mutations.

18. The method of claim 16 , wherein sequencing DNA from the tumor sample and sequencing DNA from the non-tumor sample comprises whole genome sequencing or whole exome sequencing.

19. The method of claim 16 , wherein the cfDNA sample is extracted from a fluid sample from the subject.

20. The method of claim 19 , wherein the fluid sample is a whole blood sample, a plasma sample, or a serum sample.

21. The method of claim 16 , wherein enriching the DNA fraction comprises hybrid capture-based enrichment, PCR-target enrichment, or on-sequencer enrichment.

22. The method of claim 16 , the cfDNA sample is obtained one or more times during a cancer treatment, following completion of a cancer treatment, while the subject is in remission, or coinciding with or prior to surgery.

23. A method of enriching a sample comprising circulating tumor DNA (ctDNA), comprising:

extracting cell-free DNA (cfDNA) from a fluid sample obtained from a subject with a history of cancer;

enriching, from the extracted cfDNA, fragments comprising one or more of a subset of tumor-specific somatic mutations via

(i) hybrid capture-based enrichment,

(ii) PCR-target enrichment, or

(iii) on-sequencer enrichment,

thereby obtaining a DNA fraction comprising ctDNA;

wherein the subset of tumor-specific somatic mutations is specific to the subject and selected from a set of somatic mutations determined from sequence reads from sequencing DNA from a tumor sample from the subject and sequence reads from sequencing DNA from a non-tumor sample from the subject.

24. The method of claim 23 , wherein the subset of tumor-specific somatic mutations comprises at least 10 different tumor-specific somatic mutations.

25. The method of claim 23 , wherein sequencing DNA from the tumor sample and sequencing DNA from the non-tumor sample comprises whole genome sequencing or whole exome sequencing.

26. The method of claim 23 , wherein the fluid sample is a whole blood sample, a plasma sample, or a serum sample.

27. The method of claim 23 , wherein enriching comprises hybrid capture-based enrichment.

28. The method of claim 23 , wherein enriching comprises PCR-target enrichment.

29. The method of claim 23 , the fluid sample is obtained one or more times during a cancer treatment, following completion of a cancer treatment, while the subject is in remission, or coinciding with or prior to surgery.

30. The method of claim 23 , further comprising sequencing the DNA fraction, thereby obtaining a plurality of sequence reads; and

detecting in the plurality of sequence reads the presence of a sequence read comprising any one of the subset of tumor-specific somatic mutations, wherein the presence of a sequence read comprising any one of the subset of tumor-specific somatic mutations indicates the presence of ctDNA in the fluid sample.

Assignments (3)
SECURITY INTEREST Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
CHANGE OF NAME Recorded Feb 24, 2025
From: COUNSYL, INC.
To: MYRIAD WOMEN'S HEALTH, INC.
Reel/Frame 070306/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2025
From: MAGUIRE, JARED ROBERT; CHU, CLEMENT; HAQUE, IMRAN SAEEDUL; EVANS, ERIC ANDREW; WELKER, NOAH
To: COUNSYL, INC.
Reel/Frame 070294/0693 →
Continuity (8)
Continuation 18357799 · Jul 24, 2023
Continuation 17883414 · Aug 8, 2022
Continuation 17678829 · Feb 23, 2022
Continuation 17383273 · Jul 22, 2021
Continuation 16784761 · Feb 7, 2020
Continuation 15465553 · Mar 21, 2017
Provisional Application 62311899 · Mar 22, 2016
Related Publication 20250154605A1 · May 15, 2025
References Cited (70)
US 6306597B1 · Macevicz · 2001 [cited by applicant]
US 7115400B1 · Adessi et al. · 2006 [cited by applicant]
US 7232656B2 · Balasubramanian et al. · 2007 [cited by applicant]
US 7323305B2 · Leamon et al. · 2008 [cited by applicant]
US 10597717B2 · Maguire et al. · 2020 [cited by applicant]
US 11932910B2 · Maguire et al. · 2024 [cited by applicant]
US 12024749B2 · Maguire et al. · 2024 [cited by applicant]
US 20080160580A1 · Adessi et al. · 2008 [cited by applicant]
US 20080286795A1 · Kawashima et al. · 2008 [cited by applicant]
US 20120208705A1 · Steemers et al. · 2012 [cited by applicant]
US 20130225452A1 · Pollack et al. · 2013 [cited by applicant]
US 20130261019A1 · Lin et al. · 2013 [cited by applicant]
US 20130296183A1 · Eggan et al. · 2013 [cited by applicant]
US 20140342354A1 · Evans et al. · 2014 [cited by applicant]
US 20150080266A1 · Volkmuth et al. · 2015 [cited by applicant]
US 20150301058A1 · Schettini et al. · 2015 [cited by applicant]
US 20150376700A1 · Schnall-Levin et al. · 2015 [cited by applicant]
US 20160053301A1 · Raymond et al. · 2016 [cited by applicant]
WO WO2011103236A2 · 2011 [cited by applicant]
WO WO2013112923A1 · 2013 [cited by applicant]
WO WO2014015084A2 · 2014 [cited by applicant]
WO WO2014151117A1 · 2014 [cited by applicant]
WO WO2016040901A1 · 2016 [cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool”, Journal of Molecular Biology, 1990, pp. 403-410, vol. 215, 1990 Academic Press Limited. [cited by applicant]
Botezatu et al., “Genetic Analysis of DNA Excreted in Urine: A New Approach for Detecting Specific Genomic DNA Sequences from Cells Dying in an Organism”, Clinical Chemistry, vol. 46, No. 8, May 22, 2000, pp. 1078-1084. [cited by applicant]
Branton et al., “The potential and challenges of nanopore sequencing”, Nat. Biotechnol., vol. 26, 2008, pp. 1146-1153. [cited by applicant]
Browning et al., “Haplotype phasing: Existing methods and new developments”, Nat. Rev. Genet., vol. 12, Apr. 1, 2012, pp. 703-714. [cited by applicant]
Butler et al., “Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease,” PLoS One, 10(8):e0136407, pp. 1-14 (Aug. 28, 2015). [cited by applicant]
Chan et al., “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing”, Clinical Chemistry, vol. 59… [cited by applicant]
Chen et al., “Microsatellite alterations in plasma DNA of small cell lung cancer patients”, Nature Medicine, vol. 2, No. 2, Sep. 1996, pp. 1033-1035. [cited by applicant]
Dawson et al., “Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer”, The New England Journal of Medicine, 2013, vol. 368, No. 13, pp. 1199-1209 and Supplemental Appendix. [cited by applicant]
Diehl et al., “Circulating mutant DNA to assess tumor dynamics”, Nat Med., 2008, vol. 14, No. 9, pp. 985-990. [cited by applicant]
Duncavage et al., “Hybrid Capture and Next-Generation Sequencing Identify Viral Integration Sites from Formalin-Fixed, Paraffin-Embedded Tissue”, The Journal of Molecular Diagnostics, May 3, 2011, vol. 13, No. 3, pp. 32… [cited by applicant]
Fan et al., “Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood”, PNAS, vol. 105, No. 42, Oct. 21, 2008, pp. 16266-16271. [cited by applicant]
Fierer et al., “The influence of sex, handedness, and washing on the diversity of hand surface bacteria”, Proc. Nat'l Adad. Sci., vol. 105, Nov. 18, 2008, pp. 17,994-17,999. [cited by applicant]
Forshew et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” Sci Transl Med, 4(136): 136ra68, 13 pages (May 30, 2012). [cited by applicant]
Garcia- Murillas et al., “Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer”, Sci Transl Med., 2015, vol. 7, No. 302, 13 pages. [cited by applicant]
Gnirke et al., “Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing,” Nature Biotechnology, Feb. 2009, vol. 27, No. 2 (pp. 182-189). [cited by applicant]
Gudmundsson et al., “Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility”, Nat Genet., vol. 41, No. 10, Oct. 2009, pp. 1122-1126. [cited by applicant]
Hamady et al., “Error-correcting barcoded primers allow hundreds of samples to by pyrosequenced in multiplex”, Nature Methods, vol. 5, No. 3, 2008, pp. 235-237. [cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proceedings of the National Academy of Sciences USA, vol. 89, Nov. 1992, pp. 10915-10919. [cited by applicant]
Higgins et al., “Clustal: a package for performing multiple sequence alignment on a microcomputer,” Dec. 15, 1988, Gene, vol. 73, No. 1, pp. 237-244. [cited by applicant]
Hopp et al., “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification,” Bio/Technology, Oct. 1988, vol. 6, pp. 1204-1210. [cited by applicant]
Horhota et al., “Glycerol nucleoside triphosphates: synthesis and polymerase substrate activities”, Organic Letters, Sep. 8, 2006, vol. 8, No. 23, pp. 5345-5347. [cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci., vol. 90, Jun. 1993, pp. 5873-5877. [cited by applicant]
Koide et al., “Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women,” Prenatal Diagnosis, vol. 25, No. 7, Jul. 2005, pp. 604-607. [cited by applicant]
Koren et al., One chromosome, one contig: Complete microbial genomes from long-read sequencing and assembly, Curr. Opin. Microbiol. vol. 23, Dec. 1, 2014, pp. 110-120. [cited by applicant]
Krishnan et al., Barcodes for DNA Sequencing with guaranteed error correction and capability, Electronics Letter, vol. 47, 2011, pp. 236-237. [cited by applicant]
Langmead et al., “Ultrafast and memory-efficient alignment of short DNA sequences to the human genome”, Genome Biology, Mar. 4, 2009, vol. 10, No. 3 (pp. 1-10). [cited by applicant]
Leary et al., “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing,” Science Translational Medicine, Feb. 24, 2010, vol. 2, No. 20 (pp. 1-8). [cited by applicant]
Lefrancois et al., Efficient yeast ChiP-Seq using multiplex short-read DNA sequencing, BMC Genomics, vol. 10, 2009, pp. 1-18. [cited by applicant]
Ley et al., “CDNA Sequencing of a Cytogenetically Normal Acute Myeloid Leukaemia Genome,” Nature, 456(7218):66-72 (Nov. 6, 2008). [cited by applicant]
Li et al., “The Sequence Alignment/Map format and SAMtools”, Bioinformatics, vol. 25, No. 16, 2009, pp. 2078-2079. [cited by applicant]
Lipson et al., “Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade”, J Immunother Cancer. 2014, 7 pages. [cited by applicant]
Lo et al., “Presence of fetal DNA in maternal plasma and serum”, The Lancet, vol. 350, Aug. 16, 1997, pp. 485-487. [cited by applicant]
Lutz-Freyermuth et al., “Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of … [cited by applicant]
Martin et al., “GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K+ Channel Currents”, Science, vol. 255, No. 5041, Jan. 10, 1992, pp. 192-194. [cited by applicant]
Mertes et al., “Targeted enrichment of genomic DNA regions for next-generation sequencing”, Briefings in Functional Genomics, 2011, vol. 10, No. 6, pp. 374-386. [cited by applicant]
Metzker, Michael, “Sequencing technologies—the next generation”, Nature Reviews, vol. 11, Jan. 2010, pp. 31-46. [cited by applicant]
Needleman, et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol, vol. 48, pp. 443-453 (1970). [cited by applicant]
Newman et al, “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage” Nature Medicine, May 2014, vol. 20, No. 5, pp. 548-554 and Supplementary Information (pp. 1-22). [cited by applicant]
Pereira et al., “Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers,” PLoS One 10(12):e0145754, p. 1-13 and Figure S1 and Table S1, 15 pages, total (… [cited by applicant]
Skinner et al., “Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins”, The Journal of Biological Chemistry, vol. 266, No. 22, Aug.… [cited by applicant]
Su et al., “Human Urine Contains Small, 150 to 250 Nucleotide-Sized, Soluble DNA Derived from the Circulation and May Be Useful in the Detection of Colorectal Cancer”, Journal of Molecular Diagnostics, vol. 6, No. 2, Ma… [cited by applicant]
Takai et al., “Clinical Utility of Circulating Tumor DNA for Molecular Assessment in Pancreatic Cancer,” Nature Scientific Reports, 5:18425, p. 1-10 and Supplementary Information, 43 pages, total (2015). [cited by applicant]
Thermo Fisher Scientific. “Ion AmpliSeq™ Designer provides full flexibility to sequence genes of your choice” Application Note. Ionu AmpliSeq™ Custom Panels. 4 pages, available via URL: <assets.thermofisher.com/TFS-Asse… [cited by applicant]
Turner et al., “Massively parallel exon capture and library-free resequencing across 16 genomes”, Nat. Methods, 6:315-316, 2009. [cited by applicant]
Voelkerding et al., “Next-Generation Sequencing: From Basic Research to Diagnostics”, Clinical Chemistry, vol. 55, No. 4, 2009, pp. 641-659. [cited by applicant]
Wagle et al., “High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing”, Cancer Discovery, 2012, vol. 2, No. 1, pp. 82-93. [cited by applicant]
Woo et al., “Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma”, PLoS One, 2014, vol. 9, No. 12, 15 pages. [cited by applicant]
Cited By (2)
US 12,571,053 US 12,571,055